DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nucynta (Tapentadol Hydrochloride) - Summary

 
 



NUCYNTA SUMMARY

NUCYNTA™ (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.

NUCYNTA™ (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older.


See all Nucynta indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Nucynta (Tapentadol)

Cold-induced pain linked to the garlic and mustard receptor
Source: Neurology / Neuroscience News From Medical News Today [2014.11.14]
Some people experience cold not only as feeling cold, but actually as a painful sensation. This applies even to fairly mild temperatures - anything below 20°C.

Tweet of the Week: Dr. Oz Paints Bullseye on Forehead
Source: MedPageToday.com - medical news plus CME for physicians [2014.11.14]
(MedPage Today) -- Twitter users turn the #OzInbox hashtag into "a channel for rage and shame."

Back Pain Quiz: Test Your Back Pain IQ
Source: MedicineNet Ankylosing Spondylitis Specialty [2014.11.14]
Title: Back Pain Quiz: Test Your Back Pain IQ
Category: MedicineNet Quiz
Created: 6/16/2011 3:41:00 PM
Last Editorial Review: 11/14/2014 11:37:42 AM

No Clear Winner for Relief of Diabetic Neuropathy Pain
Source: Medscape Diabetes & Endocrinology Headlines [2014.11.13]
Which is the best drug for painful diabetic neuropathy? A new systematic review has generated some interesting observations.
Medscape Medical News

Acupuncture, Exercise May Ease Pain for Breast Cancer Patients
Source: MedicineNet Acupuncture Specialty [2014.11.13]
Title: Acupuncture, Exercise May Ease Pain for Breast Cancer Patients
Category: Health News
Created: 11/13/2014 12:00:00 AM
Last Editorial Review: 11/13/2014 12:00:00 AM

more news >>

Published Studies Related to Nucynta (Tapentadol)

Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. [2012]
OBJECTIVE: To compare the effects of tapentadol-extended release versus oxycodone-controlled release for pain relief on productivity by combining evidence from different sources.

Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2011.01]
CONCLUSIONS: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.

Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients. [2011]
and nonelderly patients... CONCLUSIONS: Tapentadol IR was safe and effective for the relief of lower back

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2010.12.02]
Abstract Objective: Painful diabetic peripheral neuropathy (DPN) may not be adequately managed with available therapeutic options. This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN... Conclusions: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.

more studies >>

Clinical Trials Related to Nucynta (Tapentadol)

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin [Recruiting]
The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects requiring additional analgesia after titration to tapentadol PR 300 mg per day.

This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject reported outcomes. Since, severe low back pain with a neuropathic component, the targeted study population, is frequently treated with a combination therapy (monotherapy is often not effective enough) it is of interest to determine if tapentadol alone (combining 2 mechanisms of action in a single molecule) could be as effective as a combination of tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus combination are of interest.

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Recruiting]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy [Recruiting]
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR 50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours (SPID48) to measure analgesic effect in Korean patients with acute pain following bunionectomy.

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain [Not yet recruiting]

A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain [Not yet recruiting]

more trials >>

Reports of Suspected Nucynta (Tapentadol) Side Effects

Hallucination (21)Drug Ineffective (20)Dizziness (20)Dyspnoea (20)Nausea (19)Confusional State (17)Feeling Abnormal (17)Depression (16)Withdrawal Syndrome (16)Anxiety (14)more >>


Page last updated: 2014-11-14

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014